Company Overview

QSAM Biosciences, Inc. is a clinical-stage biotechnology and radiopharmaceutical company focused on the development of targeted therapeutic and diagnostic products for cancer and related diseases. The company primarily operates in the oncology and nuclear medicine sectors, with an emphasis on radiopharmaceutical therapies designed to deliver targeted radiation to metastatic and primary bone cancer lesions. Its core development program is CycloSam®, a radiotherapeutic candidate based on Samarium-153 linked with DOTMP technology for the treatment of bone cancer and bone marrow ablation applications.

The company’s primary strategic focus is advancing clinical development, regulatory engagement, and commercialization planning for its radiopharmaceutical platform. QSAM Biosciences evolved from earlier-stage biotechnology operations and repositioned its business around nuclear medicine and targeted radiotherapy technologies. Public disclosures and company filings indicate that its business model is centered on intellectual property development, clinical trials, licensing opportunities, and potential strategic collaborations within the oncology therapeutics market.

Business Operations

QSAM Biosciences generates its operational activity primarily through research and development initiatives rather than commercial product sales, as the company remains in the clinical development stage. Its principal business unit centers on CycloSam®, which is being evaluated for treatment applications involving skeletal metastatic disease, osteosarcoma, and bone marrow conditioning. The company’s operations include clinical trial management, regulatory affairs, intellectual property management, and relationships with specialized nuclear medicine manufacturing and distribution providers.

The company operates primarily in the United States, though its technology platform has relevance to broader international oncology and radiopharmaceutical markets. QSAM Biosciences relies on external research institutions, clinical investigators, manufacturing contractors, and regulatory consultants to support product development activities. Publicly available information identifies collaborations with medical and research institutions associated with clinical evaluation programs, although comprehensive details regarding long-term joint ventures or material international subsidiaries remain limited in public filings. Data inconclusive based on available public sources regarding large-scale international operating subsidiaries.

Strategic Position & Investments

QSAM Biosciences’ strategic direction is centered on advancing targeted radiopharmaceutical therapies in areas with unmet medical need, particularly cancers involving bone metastases and difficult-to-treat skeletal tumors. The company has emphasized progression through clinical development milestones, expansion of intellectual property protections, and potential future commercialization pathways. Its positioning within the radiopharmaceutical sector aligns with broader industry growth in precision oncology and targeted isotope-based therapeutics.

The company’s principal investment focus remains the continued development of CycloSam® and related clinical programs. Public disclosures indicate ongoing efforts tied to regulatory engagement, manufacturing readiness, and evaluation of additional therapeutic indications for Samarium-153–based technologies. QSAM Biosciences also operates within a broader industry trend involving renewed investment interest in radioligand therapy and nuclear medicine infrastructure. However, publicly verified information regarding significant acquisitions, diversified portfolio holdings, or major controlled subsidiaries remains limited.

Geographic Footprint

QSAM Biosciences is headquartered in the United States, with operations and regulatory activities primarily concentrated in the U.S. healthcare and biotechnology markets. Its clinical development activities have involved collaborations with domestic cancer treatment and research institutions specializing in oncology and nuclear medicine applications.

Although the company does not currently appear to maintain a large multinational operating structure, its therapeutic platform targets markets with global relevance due to increasing international demand for targeted oncology treatments and radiopharmaceutical technologies. The company’s strategic and commercial opportunities potentially extend across North America, Europe, and other regions with advanced nuclear medicine infrastructure, though publicly available records indicate that most operational activities remain U.S.-centered at this stage.

Leadership & Governance

QSAM Biosciences is led by executives with backgrounds in biotechnology development, finance, oncology commercialization, and corporate strategy. Leadership communications and corporate filings indicate a strategic emphasis on advancing clinical-stage radiopharmaceutical assets through disciplined capital allocation, regulatory progression, and partnership development within oncology-focused markets.

Key executives and leadership figures include:

• Douglas R. Baum – Chief Executive Officer
• Chris J. Baum – Chairman of the Board
• Dr. James Bianco – Chief Medical Officer
• John Nee – Chief Financial Officer

The company’s governance approach, as reflected in public filings and investor communications, emphasizes clinical execution, shareholder alignment, intellectual property development, and long-term participation in the growing radiopharmaceutical therapeutics sector. Publicly available information regarding founder status and historical founding leadership contains limited consistency across sources. Data inconclusive based on available public sources.